Aldeyra has since resubmitted its application, buffing it up with a “single clinical trial that achieved the primary endpoint ...

Eli Lilly and Johnson & Johnson are joining fellow Big Pharma peers in upping their investment in AI, with Lilly looking to ...

As third-quarter earnings continue to roll out, Novartis makes headlines with the second biggest acquisition of the year; ...

Already sky high after the success of its limb-girdle muscular dystrophy therapy, reported on Monday, BridgeBio’s shares rose nearly 8% more as encaleret balanced calcium levels in patients with a ...

While the FDA continues to put out guidance documents and approve drugs, some companies are already reporting delays in ...

Despite the rejection, analysts saw Regeneron’s use of an alternate filler for Eylea HD as a positive development, with BMO Capital Markets noting that this could signal the end of manufacturing ...

Mergers and acquisitions are not just for Big Pharma. A new report from Leerink Partners takes a stab at identifying the ...

Vas Narasimhan confirmed that Novartis is having weekly discussions with the Trump administration on drug pricing, but a deal ...

Phase I/II data for rese-cel point to its therapeutic potential in systemic lupus erythematosus and lupus nephritis, as well ...

Phase III data for dapirolizumab pegol presented at the 2025 conference of the American College of Rheumatology showed ...

BioMarin no longer expects to hit its $4 billion revenue target by 2027, citing various market factors such as impending ...

Executives from Eli Lilly, Merck and other companies foresee the FDA's new onshoring proposal being anything from a ...